Latest news articles

Added 10 days ago Drug news

Draft NICE guidance does not recommend Aimovig in migraine.- Novartis.

In draft guidelines, the National Institute for Health and Care Excellence (NICE) has announced that it has decided that Aimovig...

Added 1 month ago Drug news

Interim analysis of long-term study shows Zydis safe for migraine.- Biohaven Pharmaceutical.

Biohaven Pharmaceutical announced initial positive results from its ongoing long-term, open-label safety study of Zydis (rimegepant), for the acute treatment...

Added 1 month ago Drug news

Positive Phase III trial for Zydis orally dissolving tablet to treat acute migraine.- Biohaven,

Biohaven Pharmaceutical Holding Company Ltd.announced positive topline results from a randomized, controlled Phase III clinical trial (BHV 3000-303 or Study...

Search all news articles for Headache
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Load more

Guidelines

Treatment of medication overuse headache – guideline of the EFNS headache panel

Medication overuse headache is a common condition with a population-based prevalence of more than 1–2%. Treatment is based on education, withdrawal treatment (detoxification), and prophylactic treatment.

Added 7 years ago

Cluster headache and other trigemino- autonomic cephalgias

These guidelines aim to give evidence - based recommendations for the treatment of cluster headache attacks, for the prophylaxis of cluster headache, for the treatment of paroxysmal hemicranias, and for the treatment of SUNCT syndrome.

Added 7 years ago

Treatment of miscellaneous idiopathic headache disorders (group 4 of the IHS classification) – Report of an EFNS task force

Certain miscellaneous idiopathic headache disorders, which are regarded as entities, are grouped in chapter 4 of the International Classification of Headache Disorders. Recent epidemiological research suggests that these headache...

Added 7 years ago

Search all guidelines for Headache
 

Journal articles

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.

Background: Erenumab was effective and well tolerated in a pivotal clinical trial of chronic migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) versus placebo in the subgroup of patients...

Added 4 months ago

Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.

We evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with...

Added 4 months ago

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.

Calcitonin gene-related peptide plays an important role in migraine pathophysiology. Erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.

Added 4 months ago

Search all journal articles for Headache
 

Clinical trials

A Study to Explore the Long-Term Safety of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache (ENFORCE)

This is a 68-week study to evaluate the long-term safety of fremanezumab in patients with CH. Patients who complete the pivotal studies and enroll into the current study will visit the investigational center for IMP administration...

Added 6 months ago

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention

This study will evaluate the safety and tolerability of the following doses of AGN-241689: 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and...

Added 6 months ago

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine (SPARTAN)

This is a prospective randomized, double-blind, placebo-controlled study in subjects with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).

Added 1 year ago

Search all clinical trials for Headache
 

CME

Tricyclic antidepressants and headaches: systematic review and meta-analysis

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90

Persistent headache - red flag symptoms

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0

Headache and migraine: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
2
Registration required
1
Subscription fee
0
Search all CME for Headache